More On

J&J and DOJ close to settlement in Risperdal case

Government sued the pharmaceutical company over marketing the drug for unapproved uses

The Department of Justice (DOJ) and Johnson & Johnson (J&J) are close to reaching a settlement in the long-running case involving Risperdal, Reuters reports.

The case dates back to 2004 when the U.S. government began a civil investigation against J&J claiming the pharmaceutical company marketed the schizophrenic drug for unapproved illnesses, including bipolar disorder, dementia, and mood and anxiety disorders. Soon after, individual states, including Texas and Arkansas, began suing J&J over Risperdal marketing. 

According to Reuters, anonymous sources familiar with the case said the two sides are discussing a settlement of somewhere between $1.5 billion and $1.7 billion, but it could exceed $2 billion. Sources also said the DOJ and J&J are expected to reach an agreement in a few weeks.

In March, federal prosecutors rejected a proposed settlement of $1 billion with J&J because they were seeking a larger amount.

Before J&J lost its patent on Risperdal, it was the company’s best-selling drug.

Editor

Cathleen Flahardy

Bio and more articles

Join the Conversation

Advertisement. Closing in 15 seconds.